Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis

<jats:title>Abstract</jats:title><jats:sec><jats:title>Aim</jats:title><jats:p>Hepatocellular carcinoma (HCC) after sustained virologic response (SVR) has been observed even in hepatitis C virus (HCV) patients without advanced liver fibrosis. Identifying predictors for HCC incidence in patients without advanced liver fibrosis will enable efficient post‐SVR HCC surveillance. This study aimed to develop a scoring system to predict the incidence of HCC after SVR in HCV patients without advanced liver fibrosis.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A total of 1682 HCV patients without advanced liver fibrosis (defined as Fibrosis‐4 index <3.25) with no history of HCC who initiated direct‐acting antiviral treatment between September 2014 and October 2020 at 26 institutions, and achieved SVR24, were included. We divided 1682 patients into training (1122) and validation (560) cohorts.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In the multivariate analysis, baseline age ≥ 65 years (<jats:italic>p</jats:italic> = 0.030), alanine aminotransferase (ALT) levels at SVR24 ≥ 30 U/l (<jats:italic>p</jats:italic> = 0.001), and α‐fetoprotein (AFP) levels at SVR24 ≥ 5.0 ng/ml (<jats:italic>p</jats:italic> = 0.001) were independent predictors for HCC incidence in the training cohort. We developed a scoring system to predict HCC incidence after SVR24 using these three factors (1 point was added for each factor). The cumulative HCC incidence rates at 5 years were 7.1% in patients who scored 2 or 3, and no patients developed HCC in those who scored 0 in the validation cohort.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Our scoring system using the three factors of baseline age, ALT levels at SVR, and AFP levels at SVR is useful for post‐SVR HCC surveillance of patients without advanced liver fibrosis.</jats:p></jats:sec>